Search results for "LSID"

showing 10 items of 29 documents

Involvement of Nitric Oxide in Nigrostriatal Dopaminergic System Degeneration : A Neurochemical Study.

2009

The present study was undertaken to explore the involvement of nitric oxide (NO) in the 6-hydroxydopamine (6-OHDA) experimental model of Parkinson's disease (PD) in rats. The effect of pharmacological manipulation of the NO system was evaluated on striatal dopamine (DA) level decrease produced by the toxin. 7-nitroindazole (7-NI, 50 mg/kg i.p.; n= 5) pretreatment significantly restored the striatal DA contents. Conversely, 40 mg/kg i.p. of molsidomine (MOL, n= 5), an NO donor, significantly worsened the neurodegeneration (n= 5) and completely counteracted the neuroprotective effect of 7-NI (n= 5). Thus, a crucial role for NO in 6-OHDA induced neurodegeneration is suggested together with a p…

MaleIndazolesMolsidomineParkinson's disease (PD)Substantia nigraPharmacologyNitric OxideNeuroprotectionSettore BIO/09 - FisiologiaGeneral Biochemistry Genetics and Molecular BiologyNitric oxideRats Sprague-Dawleychemistry.chemical_compoundNeurochemicalHistory and Philosophy of ScienceDopaminemedicineAnimalsNitric Oxide DonorsOxidopaminenitric oxide (NO)corpus striatumGeneral Neurosciencesubstantia nigra pars compacta (SNc)Dopaminergic6-hydroxydopamine (6-OHDA)Parkinson DiseaseRatsSubstantia NigrachemistryMolsidomineNeuroscienceOxidopaminemedicine.drug
researchProduct

Nitric oxide- and cGMP-active compounds affect the discharge of substantia nigra pars reticulata neurons: in vivo evidences in the rat

2009

The nitric oxide (NO)-active drugs influence on the bioelectric activity of neurons of the pars reticulata of the substantia nigra was studied in urethane-anesthetized rats. A first group of animals was treated with 7-nitro-indazole (7-NI), a preferential inhibitor of neuronal NO synthase. In a second group of rats, electrophysiological recordings were coupled with microiontophoretic administration of Nomega-nitro-L-arginine methyl ester (L-NAME, a NO synthase inhibitor), 3-morpholino-sydnonimin-hydrocloride (SIN-1, a NO donor) and 8-Br-cGMP (a cell-permeable analogue of cGMP, the main second-messenger of NO neurotransmission). 7-NI and L-NAME caused a statistically significant decrease in …

MaleSubstantia nigra pars reticulataAction PotentialsDown-RegulationSubstantia nigraNitric Oxide Synthase Type INeurotransmissionPharmacologyBiologySettore BIO/09 - FisiologiaNitric oxidechemistry.chemical_compoundIn vivoAnimalsSingle unit electrophysiologyNitric Oxide DonorsEnzyme InhibitorsRats WistarCyclic GMPBiological PsychiatrySubstantia nigra pars reticulataNeuronsMicroiontophoresisNeural InhibitionNitric oxideIontophoresisRatsUp-RegulationSubstantia NigraPsychiatry and Mental healthElectrophysiologyNG-Nitroarginine Methyl EsterNeurologychemistryMolsidomineExcitatory postsynaptic potentialNeurology (clinical)Pars reticulataNeuroscienceSignal TransductionJournal of Neural Transmission
researchProduct

Effects of nitric oxide-active drugs on the discharge of subthalamic neurons: microiontophoretic evidence in the rat.

2006

The presence of nitric oxide (NO) synthase and of soluble guanylyl cyclase, the main NO-activated metabolic pathway, has been demonstrated in many cells of the subthalamic nucleus. In this study, the effects induced on the firing of 96 subthalamic neurons by microiontophoretically administering drugs modifying NO neurotransmission were explored in anaesthetized rats. Recorded neurons were classified into regularly and irregularly discharging on the basis of their firing pattern. Nω-nitro-l-arginine methyl ester (L-NAME; a NO synthase inhibitor), 3-morpholino-sydnonimin-hydrocloride (SIN-1; a NO donor), S-nitroso-glutathione (SNOG; another NO donor) and 8-Br-cGMP (a cell-permeable analogue o…

MaleTime FactorsAction PotentialsNeurotransmissionInhibitory postsynaptic potentialNitric OxideSettore BIO/09 - FisiologiaNitric oxideS-Nitrosoglutathionechemistry.chemical_compoundSubthalamic NucleusAnimalsNitric Oxide DonorsEnzyme InhibitorsRats WistarCyclic GMPNeuronsAnalysis of VarianceIontophoresisDose-Response Relationship DrugChemistryGeneral Neuroscience8-Br-cGMP L-NAME SIN-1 SNOG subthalamic nucleusIontophoresisThionucleotidesRatsEnzyme ActivationSubthalamic nucleusNG-Nitroarginine Methyl EsterMolsidomineS-NitrosoglutathioneExcitatory postsynaptic potentialSoluble guanylyl cyclaseNeuroscience
researchProduct

Nitric oxide-induced inhibition on striatal cells and excitation on globus pallidus neurons: a microiontophoretic study in the rat.

2003

Single units were recorded in the striatum and in the globus pallidus (GP) of urethane-anesthetized rats under microiontophoretic administration of either Nomega-nitro-L-arginine methyl ester (L-NAME, inhibitor of nitric oxide synthase), or 3-morpholino-sydnonimin-hydrocloride (SIN-1, nitric oxide, NO donor). A steady baseline firing of sporadically discharging striatal neurons (basal firing rate <0.1 spikes/s) was evoked by a pulsed microiontophoretic ejection of glutamate. On striatal neurons, microiontophoretic application of SIN-1 induced a current-dependent inhibition (11/13), whereas L-NAME administration produced a clear excitation (9/9). On GP cells, the administration of SIN-1 had …

MaleVasodilator AgentsAction PotentialsGlutamic AcidStriatumBiologyPharmacologyGlobus PallidusNitric OxideNitric oxidechemistry.chemical_compoundBasal gangliaPremovement neuronal activityAnimalsEnzyme InhibitorsRats WistarDose-Response Relationship DrugGeneral NeuroscienceGlutamate receptorIontophoresisCorpus StriatumRatsNitric oxide synthaseGlobus pallidusNG-Nitroarginine Methyl Esternervous systemchemistryMolsidomineExcitatory postsynaptic potentialbiology.proteinNeuroscienceNeuroscience letters
researchProduct

Differential effects of nitric oxide donors on basal and electrically evoked release of acetylcholine from guinea-pig myenteric neurones

1996

1. The effects of the nitric oxide (NO) donors, 3-morpholino-sydnonimine (SIN-1), S-nitroso-N-acetylpenicillamine (SNAP) and sodium nitroprusside on basal and electrically evoked release of [3H]-acetylcholine were studied in myenteric plexus longitudinal muscle preparations of the guinea-pig small intestine preincubated with [3H]-choline. 2. The NO donors concentration-dependently increased basal release of [3H]-acetylcholine. The increase in release was calcium-dependent and was prevented in the presence of tetrodotoxin. Superoxide dismutase (150 u ml-1) potentiated the effect of SIN-1. The selective inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (OD…

Malemedicine.medical_specialtyGuinea PigsMyenteric PlexusNitric Oxidechemistry.chemical_compoundInternal medicinemedicineAnimalsEnzyme InhibitorsPhosphodiesterase inhibitorMyenteric plexusPharmacologyDose-Response Relationship DrugEndothelium-derived relaxing factorAcetylcholineElectric StimulationEndocrinologychemistryMolsidomineFemaleSodium nitroprussideS-Nitroso-N-acetylpenicillamineSoluble guanylyl cyclaseZaprinastAcetylcholineResearch Articlemedicine.drugBritish Journal of Pharmacology
researchProduct

Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo

1993

The aim of our study was to evaluate the platelet antiaggregatory and hemodynamic effects of the stable prostacyclin analog iloprost and the NO-donor SIN-1, an active metabolite of molsidomine. The number of circulating platelets was determined in anesthetized male Wistar rats as a measure of in vivo platelet aggregation. Platelet count decreased from 648 +/- 25 to 476 +/- 15 x 10(3) platelets/microliter and from 578 +/- 36 to 411 +/- 40 (mean +/- SEM) in response to two repetitive injections of collagen (70 micrograms/kg body weight). Treatment with SIN-1 bolus injections (0.3 or 1 mg/kg bw) and/or continuous i.v. infusion of iloprost (0.2 or 0.4 micrograms/kg bw/min) was initiated 15 min …

Malemedicine.medical_specialtyMolsidominePlatelet AggregationPlatelet aggregationBlood PressureProstacyclinNitric Oxidechemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsPlateletIloprostRats WistarAntihypertensive AgentsActive metaboliteChemistryDrug SynergismHematologyRatsEnzyme ActivationEndocrinologyGuanylate CyclaseMolsidomineAdenylyl Cyclase InhibitorsPlatelet Aggregation InhibitorsSignal TransductionIloprostmedicine.drugGuanylate cyclaseThrombosis Research
researchProduct

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey

2011

The Fabry Outcome Survey (FOS) was established to extend the knowledge of the natural history of Fabry disease and to assess the effects of enzyme replacement therapy (ERT) with agalsidase alfa. As of March 2009, 64 boys and 34 girls with Fabry disease had enrolled in the FOS and been treated with agalsidase alfa for at least 6 months. The prevalence of symptoms tended to be reduced after 12 and 24 months of ERT in patients who experienced symptoms at baseline. In the entire population, non-significant decreases in the prevalence of gastrointestinal problems in boys and pain crises in girls were observed after 12-24 months. Kidney function and left ventricular mass indexed to height remaine…

Malemedicine.medical_specialtyPediatricsTime FactorsAdolescentRenal functionInternal medicineGeneticsmedicineHumansEnzyme Replacement TherapyChildAdverse effectGenetics (clinical)business.industryEnzyme replacement therapymedicine.diseaseFabry diseaseNatural historyTreatment OutcomeEndocrinologyEl NiñoChild Preschoolalpha-GalactosidaseFabry DiseaseFemaleObservational studybusinessAgalsidase alfaClinical Genetics
researchProduct

Involvement of PKC and NF-κB in Nitric Oxide Induced Apoptosis in Human Coronary Artery Smooth Muscle Cells

2001

Apoptosis of vascular smooth muscle cells is critically involved in progression of atherosclerosis and may prevent intimal hyperplasia in restenosis and vascular remodeling. Nitric oxide (NO) is known to induce apoptosis, but the signaling pathways still remain unclear. We investigated p53 accumulation, protein kinase C (PKC) activation and nuclear transcription factor (NF-kappaB) binding activity as possible signaling mechanisms of NO-induced apoptosis. Apoptosis was induced dose-dependently with the NO-donors sodiumnitroprusside (SNP: 232+/-48%) and SIN-1 (241+/-90% of actinomycin D induced apoptosis; means +/- SEM, *por =0.05 vs. control) in HSMC. Inhibition of PKC significantly attenuat…

Nitroprussidemedicine.medical_specialtyVascular smooth muscleIntimal hyperplasiaPhysiologyApoptosisDNA FragmentationNaphthalenesNitric OxideMuscle Smooth VascularNitric oxidechemistry.chemical_compoundNF-KappaB Inhibitor alphaRestenosisInternal medicinemedicineHumansNitric Oxide DonorsEnzyme InhibitorsCells CulturedProtein Kinase CProtein kinase CCell Nucleusbusiness.industryNF-kappa BNF-κBStaurosporinemedicine.diseaseCoronary VesselsDNA-Binding Proteinsmedicine.anatomical_structurechemistryApoptosisMolsidomineCancer researchCardiologyI-kappa B ProteinsTumor Suppressor Protein p53businessArteryCellular Physiology and Biochemistry
researchProduct

The effects of the nitric oxide donors molsidomine and SIN-1 on human polymorphonuclear leucocyte functionin vitro andex vivo

1992

The nitrovasodilator and nitric oxide donor molsidomine and its metabolite SIN-I dilate vascular smooth muscle and inhibit platelet activation by increasing intracellular concentrations of cyclic GMP We have therefore studied the effects of molsidomine and SIN-I on isolated human polymorphonuclear leucocytes (PMN)in vitro andex vivo. In vitro molsidomine dose-dependently reducedβ-glucuronidase release and the generation of superoxide anions from non-activated and from FMLP- or PAF-stimulated human PMNs. SIN-1 was equally effective in reducing (β-glucuronidase release and totally inhibited oxygen radical generation at a concentration of 580 μmol · l−1. In a double-blind, placebo-controlled, …

PharmacologyMolsidomineChemistrySuperoxideMetabolitehemic and immune systemsGeneral MedicinePharmacologyNitric oxidechemistry.chemical_compoundBiochemistryIn vivomedicinePharmacology (medical)Platelet activationNitrovasodilatorEx vivomedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease

2009

Pregnancymedicine.medical_specialtybusiness.industryTreatment outcomeMEDLINEObstetrics and GynecologyEnzyme replacement therapymedicine.diseaseFabry diseaseReproductive MedicineInternal medicinemedicinebusinessAgalsidase alfaEuropean Journal of Obstetrics &amp; Gynecology and Reproductive Biology
researchProduct